TY - JOUR
T1 - Pancreatic mucinous cystadenocarcinoma
T2 - Epidemiology and outcomes
AU - Doulamis, Ilias P.
AU - Mylonas, Konstantinos S.
AU - Kalfountzos, Christos E.
AU - Mou, Danny
AU - Haj-Ibrahim, Huzaifa
AU - Nasioudis, Dimitrios
N1 - Publisher Copyright:
© 2016 IJS Publishing Group Ltd
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background Pancreatic mucinous cystadenocarcinoma is a rare malignancy. Our aim was to investigate the demographic, pathological characteristics, treatment modalities and survival of patients with mucinous cystadenocarcinoma via the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database analysis. Materials and methods This was a retrospective study of SEER database's records on patients with mucinous cystadenocarcinoma diagnosed from 1988 to 2012. Primary outcome measures were clinico-pathological characteristics, observed and disease-specific survival. Results A total of 507 patients were identified. Median age at diagnosis was 67 years and most patients were female (68.4%). The tumors were mainly low grade (82.9%, grade I-II) and frequently localized (42.8%) in the body/tail of the pancreas (45.6%). According to Kaplan-Meier curves observed survival was 111 months (95%CI: 82.5, 139.5) vs 14 months (95% CI: 10.9, 17.1) vs 4 months (95%CI: 2.9, 5.1) for patients with localized, regional and distant disease, respectively. One-year disease-specific survival for patients with localized disease was 90.1%, vs. 56.7% for those with regional and 18.7% with distant tumor spread. Conclusions Mucinous cystadenocarcinomas tend to be low grade tumors, localized to the pancreatic body/tail. Surgery as the primary therapeutic intervention and tumor stage are independent predictors of disease-specific survival.
AB - Background Pancreatic mucinous cystadenocarcinoma is a rare malignancy. Our aim was to investigate the demographic, pathological characteristics, treatment modalities and survival of patients with mucinous cystadenocarcinoma via the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database analysis. Materials and methods This was a retrospective study of SEER database's records on patients with mucinous cystadenocarcinoma diagnosed from 1988 to 2012. Primary outcome measures were clinico-pathological characteristics, observed and disease-specific survival. Results A total of 507 patients were identified. Median age at diagnosis was 67 years and most patients were female (68.4%). The tumors were mainly low grade (82.9%, grade I-II) and frequently localized (42.8%) in the body/tail of the pancreas (45.6%). According to Kaplan-Meier curves observed survival was 111 months (95%CI: 82.5, 139.5) vs 14 months (95% CI: 10.9, 17.1) vs 4 months (95%CI: 2.9, 5.1) for patients with localized, regional and distant disease, respectively. One-year disease-specific survival for patients with localized disease was 90.1%, vs. 56.7% for those with regional and 18.7% with distant tumor spread. Conclusions Mucinous cystadenocarcinomas tend to be low grade tumors, localized to the pancreatic body/tail. Surgery as the primary therapeutic intervention and tumor stage are independent predictors of disease-specific survival.
KW - Mucinous cystadenocarcinoma
KW - Neoplasms
KW - Pancreas
UR - http://www.scopus.com/inward/record.url?scp=84988660357&partnerID=8YFLogxK
U2 - 10.1016/j.ijsu.2016.09.017
DO - 10.1016/j.ijsu.2016.09.017
M3 - Article
C2 - 27638187
AN - SCOPUS:84988660357
SN - 1743-9191
VL - 35
SP - 76
EP - 82
JO - International Journal of Surgery
JF - International Journal of Surgery
ER -